Norovirus-neutralizing Monoclonal Antibodies

Vaccines and therapies to prevent and treat Norovirus infections do not exist, despite the worldwide prevalence of Norovirus infections. Outbreaks of human gastroenteritis attributable to Norovirus commonly occur in group setting, such as hospitals, nursing homes, schools, dormitories, cruise ships and military barracks.

This technology relates to monoclonal antibodies, which specifically bind to Norovirus and have therapeutic potential. In a primate model, these antibodies stimulated a strong adaptive immune response which may produce a protective effect. These Norovirus antibodies may have application as immunoprophylaxis to protect individuals from infections or as a possible treatment for infected individuals.

Potential Commercial Applications: Competitive Advantages:
  • Therapeutic
  • Vaccine
  • Currently, no vaccines or therapies exist to prevent and treat Norovirus infections.

Zhaochun Chen (NIAID)
Robert Purcell (NIAID)
Lisbeth Kim Green (NIAID)
Stanislav Sosnovtsev (NIAID)
Karin Bok (NIAID)

Intellectual Property:
US Application No. 61/763,879

Collaboration Opportunity:

The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Maryann Puglielli, Ph.D., J.D. at

Licensing Contact:
Edward (Tedd) Fenn ,
NIH Office of Technology Transfer
Phone: 301-435-5031

OTT Reference No: E-226-2011/0

Updated: Sep-10-2013